Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck's CETP inhibitor may miss the mark for CV benefit

Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III REVEAL cardiovascular outcomes trial showing that anacetrapib (MK-0859) reduced major coronary events -- the primary endpoint defined as a composite of coronary death, myocardial

Read the full 363 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers